Form 4: Synaptogenix Director Jonathan Schechter Acquires Stock Options

Director Jonathan Schechter acquired stock options in Synaptogenix, Inc. exercisable after one year of service.

Summary

• On April 3, 2025, Jonathan Schechter, a director of Synaptogenix, Inc. [SNPX], was granted stock options to purchase 800 shares of common stock.
• The exercise price of these options is $2.28 per share.
• The options vest and become exercisable after one year of service following April 3, 2025, and expire on April 3, 2035.
• The reporting person directly owns 800 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment. This is a routine filing indicating a stock option grant to a director. It doesn't inherently suggest positive or negative performance, but rather aligns the director's interests with the company's success.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Option grants are a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• The vesting schedule of one year is fairly standard.
• Comparable companies often use similar equity-based compensation to align management interests with shareholder value.

Key Dates

Keywords

stock options, Synaptogenix, director, SNPX, Form 4, beneficial ownership, Schechter, equity securities